Oxytocin dosage: reported doses and schedule
A hormone used during childbirth; nasal social and weight-loss benefits remain unproven.
Also called: Pitocin, Syntocinon, OT, OXT, TTA-121.
Neuropeptides · Oxytocin-receptor agonist and uterotonic hormone · Evidence: Approved drug.
Typical reported dose: 25–100 mcg per injection, timing varies
- Pitocin: supervised labour infusion: Start 0.5–1 mU/min; increase by 1–2 mU/min every 30–60 minutes to the desired contraction pattern., then At 5–6 cm dilation, the rate may be reduced by similar increments. continuous infusion; adjust every 30–60 minutes, into a vein. Drug label. Studied in: Hospital obstetric patients. (source)
- Pitocin: bleeding after birth, IV: 10–40 units added to the running IV fluid; maximum 40 units per 1000 mL. Adjust rate to control uterine atony. continuous infusion adjusted to uterine response, into a vein. Drug label. Studied in: Hospital postpartum patients. (source)
- Pitocin: bleeding after birth, IM: 10 units (1 mL) intramuscularly after delivery of the placenta. one dose after delivery of the placenta, into muscle. Drug label. Studied in: Postpartum patients after placental delivery. (source)
- Pitocin: infusion after curettage: 10 units in 500 mL physiologic saline or 5% dextrose-in-water to support uterine contraction after curettage. infusion; rate individualized, into a vein. Drug label. Studied in: Patients after curettage for incomplete, inevitable or elective abortion. (source)
- Pitocin: midtrimester abortion infusion: 10–20 milliunits/minute; total dose must not exceed 30 units in 12 hours. continuous infusion; total capped over 12 hours, into a vein. Drug label. Studied in: Patients after intra-amniotic treatment for midtrimester abortion. (source)
- WHO: prevent bleeding after birth: 10 IU intramuscularly for postpartum-haemorrhage prevention. one preventive dose, into muscle. Clinician-published. Studied in: Women giving birth under skilled care. (source)
Highest studied: Highest located daily human regimen: 2.5 IU/day, about 4.2 mcg, in a weak 1953 engorgement trial..
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- PITOCIN- oxytocin injection, Par Health USA, LLC · DailyMed · 2026
- Search results summary, Health Canada · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Understanding the Risks of Compounded Drugs, FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Oxytocin 10 IU/ml Solution for infusion - Summary of Product Characteristics (SmPC), electronic medicines compendium · 2025
- Postpartum interventions to prevent postpartum haemorrhage, World Health Organization · 2025
- WHO recommendations on maternal and newborn care for a positive postnatal experience, World Health Organization · 2022
- Syntometrine, Phebra Pty Ltd · Australian Commission on Safety and Quality in Health Care · 2019
- PSUSA/00002263/201706 - periodic safety update report single assessment, EMA · 2018
- Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry, FDA · 2016
- Oxytocin (Aspen), Healthdirect Australia
- SYNTOCINON oxytocin 10 IU/1 mL injection ampoule (13383), Therapeutic Goods Administration
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.